After finishing the correction at 1.1192, EURUSD continues moving upwards to reach 1.1360; right now, it is consolidating above 1.1310. Possibly, the pair may break the range to the upside and reach 1.1380 or even extend this wave up to 1.1412. After that, the instrument may resume trading downwards with the target at 1.1287.
GBPUSD, “Great Britain Pound vs US Dollar”
After breaking 1.2568 to the upside, GBPUSD is expected to trade upwards and reach 1.2650. After that, the instrument may start a new decline to return to 1.2568, thus forming a new consolidation range between these two levels. If later the price breaks the range to the upside, the market may grow to reach 1.2780; if to the downside – resume trading downwards.
USDRUB, “US Dollar vs Russian Ruble”
USDRUB is finishing the correction at 69.60. Later, the market may resume trading inside the downtrend with the target at 67.80.
USDJPY, “US Dollar vs Japanese Yen”
After completing the correction at 108.70, USDJPY is growing to break 109.14 to the upside. Possibly, the pair may reach 109.70 and then start another decline towards 108.12.
USDCHF, “US Dollar vs Swiss Franc”
After finishing the descending wave at 0.9550, USDCHF is consolidating near the lows. If later the price breaks the range to the upside at 0.9565, the market may grow to reach 0.9590; if to the downside at 0.9545 – resume trading downwards with the target at 0.9525.
AUDUSD, “Australian Dollar vs US Dollar”
After breaking 0.6934 to the upside, AUDUSD is expected to continue growing towards 0.7014. Later, the market may fall to break 0.6934 and then form a new descending structure with the target at 0.6868.
BRENT
After breaking 40.00, Brent is expected to continue growing towards 41.00. After that, the instrument may correct to reach 38.70 and then resume trading upwards with the target at 45.50.
XAUUSD, “Gold vs US Dollar”
After finishing the ascending wave at 1720.40, Gold is moving downwards to reach 1704.60. Later, the market may break it and then continue trading downwards with the target at 1690.30.
BTCUSD, “Bitcoin vs US Dollar”
BTCUSD has finished the ascending structure at 9700.00. Today, the pair may continue trading upwards towards 10000.00 and then start another decline with the first target at 9000.00.
S&P 500
The Index has completed the correctional wave at 3094.0; right now, it is moving upwards. Possibly, today the asset may break 3133.3 and reach the next target at 3167.2. After that, the instrument may start consolidating close to the highs.
Attention! Forecasts presented in this section only reflect the author’s private opinion and should not be considered as guidance for trading. RoboForex LP bears no responsibility for trading results based on trading recommendations described in these analytical reviews.
As we can see in the daily chart, after breaking a Triangle pattern to the upside and updating the high, BTCUSD has failed to break 61.8% fibo. At the moment, the pair is trading not far from the above-mentioned pattern again. The next upside target may be 76.0% fibo at 11450.00. However, the fact that the instrument is slowing down along with a divergence on MACD indicates a possible reversal and a new decline.
In the H4 chart, after reaching the high at 10505.60, BTCUSD has quickly rebounded. At the same time, we can see a divergence on MACD, which may indicate a possible trend reversal. The first signal to confirm this scenario will be a breakout of the support at 8925.50. After that, the instrument may continue falling to reach 23.6%, 38.2%, and 50.0% fibo at 8846.00, 7907.00, and 7153.20 respectively.
ETHUSD, “Ethereum vs. US Dollar”
As we can see in the daily chart, after finishing a short-term correction around 61.8% fibo, ETHUSD has reached 76.0% fibo. Possibly, the pair may grow towards the fractal high at 288.98. At the same time, there might be a divergence on MACD to indicate a possible reversal. However, the key signal in favor of further decline will be a breakout of the support at 212.70..
As we can see in the H4 chart, the local divergence made ETHUSD start a new correction to the downside. The correctional targets are 23.6%, 38.2%, and 50.0% fibo at 214.90, 191.00, and 171.60 respectively. However, if the instrument breaks the high at 253.47, the price may continue trading upwards.
Attention! Forecasts presented in this section only reflect the author’s private opinion and should not be considered as guidance for trading. RoboForex LP bears no responsibility for trading results based on trading recommendations described in these analytical reviews.
China is the world top soybean importer, and its April imports from Brazil were nearly triple March shipments of 2.099 million tons(mt). China bought 5.939 mt of soybean from Brazil in April, according to General Administration of Customs data. Soybean imports in May, June and July are expected to top 9 mt a month, well above average levels from Brazil. At the same time US Department of Agriculture reported weekly US soybean export inspections rose nearly 2.0 million bushels from last week to 14.6 million bushels for the week of May 22-28. And USDA announced a 6.8 million bushel soybean sale to an unknown buyer yesterday, believed by many to be shipped to China. Higher exports to China are bullish for soybean prices. Nevertheless China’s soybean imports from US for the marketing year to date are 48.6% lower than the five-year average. And there were reports Beijing ordered state owned firms to halt large scale US soybean and pork purchases as US-China tensions rose. Today USDA is due to release its weekly export report, and low shipment data are a downside risk for soybean price.
The EUR/USD currency pair continues to show a steady uptrend. Since the beginning of this week, quotes growth has exceeded 250 points. Investors assess the ECB meeting. The regulator has kept key interest rates unchanged. The Central Bank has increased the crisis bond-buying program by 600 billion euros instead of the expected 500 billion. Currently, EUR/USD quotes are consolidating in the range of 1.1315-1.1380. Investors have taken a wait-and-see attitude before today’s US labor market report for May. Experts forecast quite pessimistic labor statistics. We recommend paying attention to the difference between the actual and forecasted values. Positions should be opened from key levels.
The Economic News Feed for 2020.06.05:
At 15:30 (GMT+3:00), a report on the US labor market will be published.
Indicators signal the power of buyers: the price has fixed above 50 MA and 100 MA.
The MACD histogram is in the positive zone, indicating the bullish sentiment.
Stochastic Oscillator is near the overbought zone, the %K line has crossed the %D line. There are no signals at the moment.
Trading recommendations
Support levels: 1.1315, 1.1250, 1.1190
Resistance levels: 1.1380, 1.1450
If the price fixes above 1.1380, further growth of EUR/USD quotes is expected. The movement is tending to 1.1430-1.1450.
An alternative could be a decrease in the EUR/USD currency pair to 1.1260-1.1230.
The GBP/USD currency pair
Technical indicators of the currency pair:
Prev Open: 1.25710
Open: 1.25966
% chg. over the last day: +0.17
Day’s range: 1.25840 – 1.26903
52 wk range: 1.1466 – 1.3516
GBP/USD quotes show a pronounced uptrend. The British pound has approached the $1.27 mark. The 1.2610 level is already a “mirror” support. The demand for risky assets is still high. At the moment, financial market participants have taken a wait-and-see attitude before labor statistics in the US for May. We recommend opening positions from key levels.
The news feed on the UK economy is calm today.
Indicators signal the power of buyers: the price has fixed above 50 MA and 100 MA.
The MACD histogram is in the positive zone and above the signal line, which gives a strong signal to buy GBP/USD.
Stochastic Oscillator is near the overbought zone, the %K line has crossed the %D line. There are no signals at the moment.
Trading recommendations
Support levels: 1.2610, 1.2525, 1.2480
Resistance levels: 1.2685, 1.2750, 1.2800
If the price fixes above 1.2685, further growth of GBP/USD quotes is expected. The movement is tending to 1.2750-1.2780.
An alternative could be a decrease in the GBP/USD currency pair to 1.2560-1.2530.
The USD/CAD currency pair
Technical indicators of the currency pair:
Prev Open: 1.34964
Open: 1.34962
% chg. over the last day: -0.01
Day’s range: 1.34621 – 1.35126
52 wk range: 1.2949 – 1.4668
USD/CAD quotes continue to consolidate. There is no defined trend. At the moment, the local support and resistance levels are 1.3460 and 1.3520, respectively. We expect the release of reports on the labor market in the United States and Canada. We also recommend paying attention to the dynamics of “black gold” prices. Positions should be opened from key levels.
The News Feed on Canada’s Economy:
– Data on the labor market of Canada at 15:30 (GMT+3:00);
– Ivey PMI at 17:00 (GMT+3:00).
Indicators do not give accurate signals: the price has crossed 50 MA.
The MACD histogram has started declining, which indicates the development of bearish sentiment.
Stochastic Oscillator is near the oversold zone, the %K line has crossed the %D line. There are no signals at the moment.
Trading recommendations
Support levels: 1.3460, 1.3400
Resistance levels: 1.3520, 1.3585, 1.3675
If the price fixes below 1.3460, a further drop in USD/CAD quotes is expected. The movement is tending to the round level of 1.3400.
An alternative could be the growth of the USD/CAD currency pair to 1.3560-1.3600.
The USD/JPY currency pair
Technical indicators of the currency pair:
Prev Open: 108.869
Open: 109.147
% chg. over the last day: +0.22
Day’s range: 109.044 – 109.427
52 wk range: 101.19 – 112.41
Purchases still prevail on the USD/JPY currency pair. The trading instrument has updated local highs again. At the moment, USD/JPY quotes are testing the resistance level of 109.40. The 109.10 mark is already a “mirror” support. Further growth of the USD/JPY currency pair is possible. We recommend paying attention to the report on the US labor market. Positions should be opened from key levels.
The news feed on Japan’s economy is calm.
Indicators signal the power of buyers: the price has fixed above 50 MA and 100 MA.
The MACD histogram is in the positive zone, indicating the bullish sentiment.
Stochastic Oscillator is near the overbought zone, the %K line has crossed the %D line. There are no signals at the moment.
Trading recommendations
Support levels: 109.10, 108.85, 108.60
Resistance levels: 109.40, 110.00
If the price fixes above 109.40, further growth of the USD/JPY quotes is expected. The movement is tending to 110.00-110.20.
An alternative could be a decrease in the USD/JPY currency pair to 108.80-108.50.
The US dollar has continued to decline against a basket of currency majors. The US currency is under pressure due to weak economic data. Thus, initial jobless claims increased again and counted to 1,877K, which exceeded the expectations of experts who predicted 1,800K. Investors expect the publication of reports on the US and Canadian labor markets. Yesterday, the dollar index (#DX) updated local lows again and closed in the negative zone (-0.62%).
The single currency has been growing relative to a basket of currencies after the ECB meeting. Following the meeting, the regulator announced that it had expanded the Pandemic Emergency Purchase Program (PEPP) by 600 billion euros, and also reported that it would continue to buy assets under the PEPP at least until the end of June 2021. At the same time, the ECB has kept key interest rates at the same level.
The “black gold” prices have been growing. Currently, futures for the WTI crude oil are testing the $38.10 mark per barrel.
Market indicators
Yesterday, there was the bearish sentiment in the US stock market: #SPY (-0.26%), #DIA (-0.06%), #QQQ (-0.70%).
The 10-year US government bonds yield has grown again. At the moment, the indicator is at the level of 0.85-0.86%.
The news feed on 2020.06.05:
– US labor market data at 15:30 (GMT+3:00);
– Data on the labor market of Canada at 15:30 (GMT+3:00);
While the EUR/USD kept its bullish momentum after the sustainable break above 1.1000, which has laid the path up to 1.1200 as an initial target, so today could be the starting point of a corrective move back towards 1.1000.
This could be driven by today’s Non-Farm Payrolls report. While the data is expected to come in at -8 million, Wednesday’s ADP employment report leaves some room for optimism: while private businesses in the US fired 2.76 million workers in May, figures nevertheless beat the market forecasts of a 9 million drop.
Still, the EU commission’s proposal of a 750 Billion-Euro fiscal stimulus package with 500 billion Euro in grants and 250 billion in loans can be considered a first step toward a transfer union, leaving the Euro with an overall bullish tendency. That might be especially true, after the ECB boosted the size of its PEPP program yesterday to 1.35 trillion Euros with being set to run through at least the end of June 2021.
That said, a corrective move in the EUR/USD finds a solid support and potential Long-trigger around 1.1000, the breakout region, with the overall target above 1.1200/30 around 1.1400/50 staying active.
Source: Admiral Markets MT5 with MT5SE Add-on EUR/USD Daily chart (between April 5, 2019, to June 4, 2020). Accessed: June 4, 2020, at 10:00pm GMT – Please note: Past performance is not a reliable indicator of future results, or future performance.
In 2015, the value of the EUR/USD fell by 10.2%, in 2016, it fell by 3.2%, in 2017, it increased by 13.92%, 2018, it fell by 4.4%, 2019, it fell by 2.2%, meaning that after five years, it was down by 7.3%.
Discover the world’s #1 multi-asset platform
Admiral Markets offers professional traders the ability to trade with a custom, upgraded version of MetaTrader 5, allowing you to experience trading at a significantly higher, more rewarding level. Experience benefits such as the addition of the Market Heat Map, so you can compare various currency pairs to see which ones might be lucrative investments, access real-time trading data, and so much more. Click the banner below to start your FREE download of MT5 Supreme Edition!
Disclaimer: The given data provides additional information regarding all analysis, estimates, prognosis, forecasts or other similar assessments or information (hereinafter “Analysis”) published on the website of Admiral Markets. Before making any investment decisions please pay close attention to the following:
This is a marketing communication. The analysis is published for informative purposes only and are in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Any investment decision is made by each client alone whereas Admiral Markets shall not be responsible for any loss or damage arising from any such decision, whether or not based on the Analysis.
Each of the Analysis is prepared by an independent analyst (Jens Klatt, Professional Trader and Analyst, hereinafter “Author”) based on the Author’s personal estimations.
To ensure that the interests of the clients would be protected and objectivity of the Analysis would not be damaged Admiral Markets has established relevant internal procedures for prevention and management of conflicts of interest.
Whilst every reasonable effort is taken to ensure that all sources of the Analysis are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admiral Markets does not guarantee the accuracy or completeness of any information contained within the Analysis. The presented figures refer that refer to any past performance is not a reliable indicator of future results.
The contents of the Analysis should not be construed as an express or implied promise, guarantee or implication by Admiral Markets that the client shall profit from the strategies therein or that losses in connection therewith may or shall be limited.
Any kind of previous or modeled performance of financial instruments indicated within the Publication should not be construed as an express or implied promise, guarantee or implication by Admiral Markets for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.
The projections included in the Analysis may be subject to additional fees, taxes or other charges, depending on the subject of the Publication. The price list applicable to the services provided by Admiral Markets is publicly available from the website of Admiral Markets.
Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, you should make sure that you understand all the risks
– Bitcoin – already one of the year’s best-performing assets – is likely to “soar in value” this year with central banks’ money printing agendas and a spike in public interest.
This is the bullish comment from the CEO of deVere Group, one of the world’s largest financial advisory and fintech organzsations.
It follows a wider positive investor sentiment regarding the leading cryptocurrency. This week Bloomberg analysts said in a note that it could jump to $20,000 in 2020.
Mr Green affirms: “Bitcoin price is already up around 30% from the beginning of the year, putting it on track to be one of the year’s best-performing assets.
“I believe it would be surprising not to see Bitcoin soar in value further throughout this year for three key reasons.
“First, the massive money-printing, or quantitative easing, programmes currently being rolled-out by central banks around the globe devalue traditional currencies and provide a boost for other recognised stores of value, such as Bitcoin and gold.
“Second, the global health emergency has been accelerating the demand and need for digital money.
“And third is that it is a legitimate hedge against longer-term inflation concerns.”
He continues: “Globally, we have seen client interest in Bitcoin, and other cryptocurrencies such as ETH, spike since the beginning of May.
“There’s been about a 25% month-on-month jump in enquiries about deVere Crypto, our crypto exchange app.
“We largely attribute this to the pandemic collectively focusing minds on readjusting to a new world.
“Of course, our lives in this new era, which was on its way but which has been ushered in faster due to Covid-19, will be increasingly tech-driven. This includes our financial lives, meaning digital currencies such as Bitcoin, amongst other fintech [financial technology] solutions.”
Geopolitical risks, including the heightening of U.S.-China tensions, Brexit and the U.S. presidential election can also be “expected to serve as a boost for Bitcoin” says Mr Green.
“Investors will increase exposure to decentralized, non-sovereign, secure digital currencies, such as Bitcoin, to help shield them from the potential issues in traditional markets.”
The deVere CEO concludes: “2020’s global public health emergency, the record-shattering policies implemented to soothe economic downturns, political uncertainty and social unrest can be expected to drive the price of Bitcoin upwards.”
About:
deVere Group is one of the world’s largest independent advisors of specialist global financial solutions to international, local mass affluent, and high-net-worth clients. It has a network of more than 70 offices across the world, over 80,000 clients and $12bn under advisement.
The Dollar index (DXY) has broken below the 97 psychological level for the first time since March and is set to wrap up three consecutive weeks of declines. Having returned to pre-pandemic levels, the Dollar’s tumble is an overt sign of the risk-on stance in the markets.
The Euro’s climb is having a major influence on the DXY decline, with the former accounting for 57.6 percent of the index’s total weighting. EURUSD’s breaching of the 1.1350 mark as the European Central Bank added €600 billion to its emergency bond-buying stimulus package at its meeting yesterday is exerting further downward pressure on the DXY.
The US Dollar’s decline also comes ahead of the May non-farm payrolls due later Friday. Markets are forecasting a contraction of 7.5 million jobs last month, after the historic loss of over 20 million in the prior report, while the unemployment rate is expected to breach 19 percent. Despite the carnage evident in the US jobs market left in the wake of Covid-19, global investors have grown accustomed to this narrative since US weekly jobless claims began soaring in the second half of March. Hence, financial markets are likely to look past today’s jobs numbers, barring any massive surprise, especially as the May 12 cut-off for the report points to the data not considering any re-opening measures in the second half of the month.
From a technical perspective, the DXY looks poised for a significant rebound, with the 14-day relative strength index (RSI) having broken into oversold territory. Previous forays below the 30 line on the RSI, most recently in December and March, subsequently led to rallies in the Greenback. However, the downward momentum was not as forceful during those two previous episodes, so it remains to be seen how much the Dollar can pare its losses amid the present risk-on environment. At least Dollar bulls can take heart from the fact that since 2019, the DXY’s ventures below its 200-day moving average have not lasted long.
Should the US dollar continue faltering, the 96 support level could be called into action once more, as was the case on the final trading day of 2019. While investors unpick the risk premiums accumulated at the height of the pandemic with the Greenback set to unwind more of its gains from recent months, we are unlikely to see a capitulation in the face of the global recession expected for the year.
Disclaimer: The content in this article comprises personal opinions and should not be construed as containing personal and/or other investment advice and/or an offer of and/or solicitation for any transactions in financial instruments and/or a guarantee and/or prediction of future performance. ForexTime (FXTM), its affiliates, agents, directors, officers or employees do not guarantee the accuracy, validity, timeliness or completeness, of any information or data made available and assume no liability as to any loss arising from any investment based on the same.
Global stocks are rising today after a mixed session on Thursday ahead of US employment report expected to show nonfarm payrolls fell in May by 8 million jobs after a record 20.54 million plunge in April. Markets’ advance paused Thursday on US Labor department report showing over 43 million Americans have lost their jobs in the last eleven weeks.
Forex news
Currency Pair
Change
EUR USD
+0.1%
GBP USD
+3.1%
USD JPY
+1.48%
The Dollar weakening continues today ahead of May jobs report expected to show US unemployment rate jumped to 19.8% from 14.7% in April. The live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, lost 0.5% Thursday after reports initial jobless claims jumped another 1.9 million last week while trade deficit widened nearly 17% in April to $49.4 billion. Both GBP/USD and EUR/USD continued climbing yesterday as the European Central Bank announced it would expand its Pandemic Emergency Purchase Program by €600 billion, or $674.5 billion and extend the program until June 2021. Both pairs are higher currently. Both AUD/USD and USD/JPY continued advancing yesterday with the dynamics intact for both pairs currently.
Stock Market news
Indices
Change
Dow Jones Index
+1.44%
Nikkei Index
+1.55%
Hang Seng Index
+1.56%
Australian Stock Index
+0.71%
Futures on three main US stock indexes are in the black currently after a mixed performance Thursday. Stock indexes paused yesterday while Dow eked a marginal gain led by 6.4% jump in Boeing on signs of rebound in air travel : the three main US stock indexes recorded daily returns ranging from -0.7% to +0.04%. European stock indexes are retracing higher today after ending solidly lower Thursday led by auto stocks. Asian indexes are mostly higher today led by Nikkei while thousands in Hong Kong defy ban to mark Tiananmen anniversary.
Commodity Market news
Commodities
Change
Brent Crude Oil
+1.92%
WTI Crude
+1.32%
Brent is extending gains today. Oil prices rose yesterday on reports the Organization of the Petroleum Exporting Countries and its major allies, including Russia, a group known as OPEC+, achieved a compliance of 89% with the output cut deal reached in April. They have yet to announce a new meeting date. The US oil benchmark West Texas Intermediate (WTI) futures ended higher yesterday: July WTI gained 0.3% and is higher currently. August Brent crude closed 0.5% higher at $39.99 a barrel on Thursday.
Gold Market News
Metals
Change
Gold
-0.3%
Gold prices are edging lower today . August rose 1.3% to $1727.40 an ounce on Thursday.
Note: This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.
Recently presented results from Enlivex Therapeutics’ Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report.
In a June 1 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Enlivex Therapeutics Ltd.’s (ENLV:NASDAQ) Allocetra demonstrated multifaceted immune system rebalancing in sepsis patients during a Phase 1b trial.
Selvaraju relayed that these results were presented by Enlivex at the International Society for Cellular Therapy conference held last week virtually. Along with a recap of safety and efficacy data, the data included a new endpoint analysis that “demonstrated the potential of Allocetra to resolve cytokine storms with heterogeneous underlying pathologies,” he wrote.
The analyst reviewed the findings presented at the conference. Enlivex’s Phase 1b study compared the levels after receiving Allocetra to baseline of more than 30 immune modulators in the participants, all sepsis patients. Results showed that after treatment with Allocetra, abnormal immune modulators either returned to or toward homeostasis. For instance, white blood cells and neutrophils returned to within normal limits in all evaluated patients.
“The fact that trends towards normalization were observed not only across multiple inflammatory markers, spanning different categories, as well as immune cell counts, but across all patients assessed, gives us confidence that these data prove the hypothesis that Allocetra achieves broad resetting of the immune system,” Selvaraju highlighted.
This return to homeostasis led to decreased or resolved inflammation, improvements in sequential organ failure assessment and reduced hospital and intensive care unit (ICU) stays. “We believe that the close relationship between observed reductions in inflammatory biomarkers and the clinical outcomes observed bodes very well for future development of Allocetra as a treatment for sepsis,” commented Selvaraju.
In Q4/20, Enlivex intends to follow up its Phase 1b study with a controlled, randomized Phase 2b trial. If the study starts as planned, topline data could be available by late 2021.
“Positive data could prove sufficient to support regulatory approval, in our view, given the unmet need in severe sepsis, which carries a 50% mortality rate, accounting for the deaths of 270,000 Americans each year,” indicated Selvaraju.
As such, an accelerated approval pathway for Allocetra in sepsis is likely as is the potential for “lucrative” pricing given that its use would decrease the time patients spent in a hospital intensive care unit.
Potential stock moving events for Enlivex in 2020 are the release of additional data on sepsis and graft versus host disease and results from its COVID-19 trial.
“We feel investors should consider investment in Enlivex given the context of the plethora of near- and medium-term clinical development-related catalysts for Allocetra,” Selvaraju noted.
H.C. Wainwright & Co. has a Buy rating and a 12-month target price of $22 per share on Enlivex Therapeutics. The stock is currently trading at about $5.35 per share.
Disclosure: 1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. 6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures from H.C. Wainwright & Co., Enlivex Therapeutics Ltd., Company Update, June 1, 2020
Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.
I, Raghuram Selvaraju, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Enlivex Therapeutics Ltd. (including, without limitation, any option, right, warrant, future, long or short position).
As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Enlivex Therapeutics Ltd.
Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Enlivex Therapeutics Ltd. for non-investment banking services in the previous 12 months.
The Firm or its affiliates did receive compensation from Enlivex Therapeutics Ltd. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Enlivex Therapeutics Ltd. during the past 12 months.
The Firm does not make a market in Enlivex Therapeutics Ltd. as of the date of this research report.
